Prognostic value of interim [68Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapy
European Radiology · 2024
DOI: 10.1007/s00330-024-11116-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Radiology, 2024. Verfasst von Eonwoo Shin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Positron Emission Tomography Computed Tomography, Octreotide, Organometallic Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Ministry of Health and Welfare.
Abstract (Originalsprache)
OBJECTIVES: This study evaluated the prognostic value of basal and interim [68Ga]Ga-DOTA-TOC PET/CT in patients with locally advanced or metastatic neuroendocrine tumour (NET) who received peptide receptor radionuclide therapy (PRRT). METHODS: Patients with NET who received PRRT with [177Lu]Lu-DOTA-TATE at our institution were retrospectively reviewed. Among them, patients who underwent both basal and interim (after two cycles of PRRT) [68Ga]Ga-DOTA-TOC PET/CT were included. Alongside clinicopathologic parameters, PET parameters of maximum standardised uptake value (SUVmax), tumour-to-liver ratio (TLR), whole tumour volume (WTV) and total receptor expression (TRE: WTV multiplied by mean standardised uptake value) were obtained from basal and interim [68Ga]Ga-DOTA-TOC PET/CT, and their proportional changes (∆) were assessed for associations with progression-free survival (PFS) using Kaplan-Meier analysis, log-rank tests, and a Cox proportional-hazards regression model. RESULTS: Twenty-four patients were finally included (10 men and 14 women, median age of 56.5 years, age range 32-74 years). Among them, 16 patients (66.7%) experienced disease progression. In univariate analysis, high ∆WTV (≥ -10%, hazard ratio [HR] = 3.053 [1.003-9.289], p = 0.049) and high ∆TRE (≥ -21%, HR = 3.567 [1.144-11.122], p = 0.028) were significantly associated with shorter PFS. In multivariate analyses adjusted for WHO grade, high ∆WTV (HR = 3.345 [1.055-10.601], p = 0.043) and high ∆TRE (HR = 3.894 [1.194-12.695], p = 0.024) were significant predictors of shorter PFS. CONCLUSION: The study demonstrates that basal and interim [68Ga]Ga-DOTA-TOC PET/CT scans, through proportional changes in WTV and TRE, effectively predict PFS in neuroendocrine tumour patients receiving PRRT. KEY POINTS: Question Peptide receptor radionuclide therapy is utilised for patients with somatostatin receptor-positive well-differentiated neuroendocrine tumours; however, prognostic predictors are not well established. Findings Progression-free survival was significantly associated with the proportional change in whole tumour volume and total receptor expression between basal and interim [68Ga]Ga-DOTA-TOC PET/CT. Clinical relevance Interim [68Ga]Ga-DOTA-TOC PET/CT can serve as a valuable imaging method to predict prognosis of peptide receptor radionuclide therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Nuclear Medicine, GangNeung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea.
- Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. kyi821209@naver.com.
- Theranostics Center, Asan Cancer Institute, Asan Medical Center, Seoul, Republic of Korea. kyi821209@naver.com.
- Theranostics Center, Asan Cancer Institute, Asan Medical Center, Seoul, Republic of Korea. yooc@amc.seoul.kr.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. yooc@amc.seoul.kr.
Förderung
- Ministry of Health and Welfare
Zitieren
APA
Shin, E., Kim, Y. I., Yoo, C., Shin, Y., Ryoo, B. Y., Lee, D. Y., & Ryu, J. S. (2024). Prognostic value of interim [68Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapy. European Radiology. https://doi.org/10.1007/s00330-024-11116-5
Vancouver
Shin E, Kim YI, Yoo C, Shin Y, Ryoo BY, Lee DY, et al. Prognostic value of interim [68Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapy. European Radiology. 2024. doi:10.1007/s00330-024-11116-5
BibTeX
@article{Shin2024,
author = {Shin, Eonwoo and Kim, Yong-Il and Yoo, Changhoon and Shin, Yeokyeong and Ryoo, Baek-Yeol and Lee, Dong Yun and Ryu, Jin-Sook},
title = {Prognostic value of interim [68Ga]Ga-DOTA-TOC PET/CT in patients with neuroendocrine tumour who underwent peptide receptor radionuclide therapy},
journal = {European Radiology},
year = {2024},
doi = {10.1007/s00330-024-11116-5}
}
EUVIMED